IL2 and primary cutaneous T-cell non-Hodgkin lymphoma: The strongest candidate drug of all in terms of degree of association is denileukin diftitox (an IL2 binding cytocidal agent) that is currently used in cutaneous T-cell lymphoma, although its action on IL2 is agonistsic/binding.